Neurol. praxi. 2014;15(3):155-157

Long-term treatment with intraduodenal levodopa - case report of three patients

MUDr. Marek Baláž, Ph.D.1, MUDr. Bohuslav Kianička, Ph.D.2, prof. MUDr. Martin Bareš, Ph.D.1
1 Centrum pro abnormní pohyby a parkinsonizmus, I. neurologická klinika FN u sv. Anny a LF MU, Brno
2 Gastroenterologické oddělení, II. interní klinika FN u sv. Anny a LF MU, Brno

We present case reports of three patients with Parkinson‘s disease (PD) treated with intradudodenal levodopa – Duodopa. Duodopa enables continuous administration of dopaminergicv treatment indicated for patients with late motor complications. Administration of levodopa into the jejunal part of duodenum and easy dose setting leads to stable plasma levels of levodopa and an improvement of motor state of patients with PD. This invasive procedure plays an important role in therapy of late motor complications of PD.

Keywords: Parkinson´s disease, intraduodenal levodopa, case reports

Published: June 9, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Baláž M, Kianička B, Bareš M. Long-term treatment with intraduodenal levodopa - case report of three patients. Neurol. praxi. 2014;15(3):155-157.
Download citation

References

  1. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord. 2009; (Suppl 4): S97-100. Go to original source... Go to PubMed...
  2. Bareš M. Pozdní hybné komplikace Parkinsonovy nemociwearing-off fenomén a další motorické komplikace. Neurol. praxi 2008; 9(2): 96-99.
  3. Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. Eur J Neurol. 2012; 19(12): 1502-1508. Go to original source... Go to PubMed...
  4. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009 Jul 30; 24(10): 1468-1474. Go to original source... Go to PubMed...
  5. de Lau LML, Giesbergen PCLM, de Rijk MC Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004; 63: 1240-1244. Go to original source... Go to PubMed...
  6. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother. 2006, Oct; 6(10): 1403-1411. Go to original source... Go to PubMed...
  7. Wright BA, Waters CH. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. Expert Rev Neurother. 2013 Jun; 13(6): 719-729. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.